Advanced searches left 3/3

Cell (Biology) - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 August 2022

* If you want to update the article please login/register

Mature B-Cell Lymphoma And Leukemia Study III

In the United States and selected geographic regions, this report will describe the distribution and frequency of XLP gene mutations causing B-cell lymphomas. This report will detail the prevalence of EBV-positive B-cell lymphomas in the United States and selected geographic regions around the world, as well as the distribution of EBV protein and gene expression in EBV-positive lymphomas in EBV-positive lymphomas; and it will compare EBV protein and gene expression in EBV-positive lymphomas. Secondary Objective: To determine the complete response rate, event-free survival, and overall survival in patients with Burkitt lymphoma, Burkitt leukemia, and diffuse large B-cell lymphoma treated with a stage-adapted program based on the St. Jude B-cell II protocol, in patients with Burkitt lymphoma, Burkitt leukemia/B-cell acute leukemia, and diffuse large B-cell lymphoma.

Source link: https://clinicaltrials.gov/ct2/show/NCT01046825


Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols

Background: Several clinical trials are ongoing in the National Cancer Institute Surgery Branch, in which patients are given autologous lymphocytes with anti-tumor antibodies isolated from either peripheral blood mononuclear cells or tumor-infiltrating lymphocytes are in progress. All adoptive cell therapy protocols recommend that certain cell characteristics be tested and fulfilled prior to enrollment. The goal: To obtain autologous blood, stem cells, and/or tumor tissue from patients with cancer research and/or ex vivo generation of autologous anti-tumor lymphocytes for future enrollment in an NCI-SB adoptive cell therapy clinical trial. How to obtain allogeneic PBMC from healthy volunteers for use in generating anti-tumor patient lymphocytes ex vivo. Patients with cancer must be over > 18 years old and meet the laboratory safety standards for infection surveillance that was included in all the cell therapy research studies. Healthy volunteers for PBMC must meet the FDA's safety evaluation standards for donation of blood products such as HBsAg, HBc, HCV, HIV, HTLV, Trypanosoma cruzi, West Nile Virus, and syphilis. Volunteers for whole blood donation must comply with the safety assessment criteria established by the NIH Clinical Center Department of Transfusion Medicine Blood Bank for screening of allogeneic whole blood donors. Structure: Once a cancer patient is found to be a candidate for one of the NCI-SB's clinical trials, they will undergo apheresis and/or tumor resection for future medical or research purposes.

Source link: https://clinicaltrials.gov/ct2/show/NCT00068003


Cellular Composition of the Human Colon Using Single-cell RNA and Single-cell ATAC-sequencing.

The distal colon has a higher incidence of ulcerative colitis, diverticulitis, and chromosomal instability cancer, while chromosomal instability-induced cancer is more prevalent in the proximal colon ischemic colitis, collagenous colitis, and microsatellite instability. We will be able to map open regions in the cell's DNA and RNA by using scRNAseq and scATACseq, providing us with a unique "map" of the cells in the colon as well as gene expression. chromatin accessibility is in conjunction with gene expression data, making it an extremely useful tool to investigate cell type specific regulatory DNA interactions. The colonists will eventually have a detailed map of the colon, as well as the colonists' influence on systemic diseases such as type II diabetes, which may lead to a more complete picture of the colon.

Source link: https://clinicaltrials.gov/ct2/show/NCT05195502


Cellular Composition of the Human Appendix Using Single-cell RNA and Single-cell ATAC-sequencing.

The human appendix was seen as a rudimentary organ with no specific role in the human body until recently. The appendix has nearly circumferential lymphoid follicles in the submucosa and lamina propria, and thus becomes a secondary lymphoid organ. Comparative to the large intestine, the appendix's greater number of CD5+, CD19+, Immunoglobulin-secretive IgG, and secretive IgA cells is present in the appendix. a human appendix is seen with a high number of intra-epithelial M-cells, as well as human leukocyte antigen D-related T and B cells, which may play a role in bacterial homeostasis in the large intestine5 and entero-endocrine regulation6. We will be able to map open regions in the cell's DNA and RNA using scRNAseq and scATACseq, thus providing us with a unique "map" of the cells in the appendix as well as gene expression9-11. Chronin accessibility is in conjunction with gene expression data a highly useful tool to investigate cell type specific regulatory DNA interactions with the emergence of scATACseq. We'll extract immune cells from the Peyeru00b4s plaques to further investigate the appendix's immunological aspects. Lastly, full blood will be extracted in order to better analyze metabolic risk factors related to appendix u00b4 metabolic regulation.

Source link: https://clinicaltrials.gov/ct2/show/NCT05209061


Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study

The Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality study is based on the results that researchers have made in treating spinal cord injury using bone marrow stem cells. The SciExVR study uses spinal needle injections, meaning the BMSC are placed next to the spinal canals that flow through the vertebral foramen of the vertebral bodies. sensory pathways; dorsal root ganglia at and below the site; and autonomic ganglia. Broken cells in the spinal cord, spinal cord, spinal nerves, and paravertebral ganglion could cause the earliest time for BMSC's to proliferate within, above and below the location of the spinal cord injury, as well as interaction with damaged cells in the spinal cord, spinal cord roots, spinal nerves, and paravertebral ganglion. Patients in Arm 1 BMSC therapy do follow up with their own neurologists at 1,3,6 and 12 months after a briefing period. Arm 2 is thought to have boosted upper and lower motor neurons, sensor neurons, and sensory receptors such as exteroceptors and condoms, which may, in the absence of BMSC, aid in the regeneration or reactivation of spinal cord pathways. Patients in Arm 3 require a similar follow-up and may use virtual reality headsets or equivalent to enhance visualization of movement of the lower extremities and/or sensory feedback.

Source link: https://clinicaltrials.gov/ct2/show/NCT03225625


Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis

MS has many variations that result in new signs in either isolated attacks or chronic symptoms that have deteriorated. In the majority of cases, severe side effects or non-responsive cases to traditional MS drugs on the market haven't been proven to be safe, completely safe, or clinically effective. This demyelination is thought to promote inflammatory reactions caused by a T-cell lymphocyte group that seems to distinguish patient's own myelin as foreign and continues to blame it for "autoreactive lymphocytes" ("autoreactive lymphocytes). With the advent of convenient adipose harvesting and processing in closed systems, as well as the ability to quickly and safely obtain a significant number of stem/stromal cells, autologous stem/stromal cells are being used. This autologous cell group, isolated and concentrated cells within the stromal vascular fraction SVF by enzymatic digestion, can be transported via intravascular routes. Since these cells are so small, there is a possibility that they will pass into the cerebral fluids of the CNS central nervous system, if this cells are defective of the blood brain barrier BBB or are small enough to pass into the CNS central nervous system's fluids. With and without contrast, the introduction of a sophisticated analytic device would be used to assess changes in the location, numbers, volumes, demyelination of brain lesions detected by MRI with and without contrast. This is done as a comparative study at intervals from baseline to 6 months minimum, and annually as available for monitoring central nervous system CNS changes over time and correlated with clinical transitions.

Source link: https://clinicaltrials.gov/ct2/show/NCT03461419


Stem Cell Factor, a Potential Biological Marker of Skin Involvement in Systemic Sclerosis?

Systemic sclerosis is mainly divided into two subtypes, mainly according to the degree of dermatological involvement: limited and diffuse systemic sclerosis. It is also known that endothelial cells interact with mast cells during the production of Stem Cell Factor, triggering cell proliferation and differentiation. TGFu03b2-infused mast cell cells, which produce TGFu03b2, have infiltrated the damaged skin tissue tissues in systemic sclerosis. Patients with systemic sclerosis, according to Kihira et al's team, there was a significant SCF content in the serum of patients with systemic sclerosis. SCF is a potential skin biomarker of skin involvement in patients with diffuse scleroderma and those with limited scleroderma. The investigators will be able to investigate this potential route of fibrosis in the serum of patients suffering from systemic sclerosis by increasing the dosage of SCF in patients with diffuse scleroderma, according to hypothesizing that the dosage of SCF in the serum of patients with systemic sclerosis will be higher in patients with SCF in patients with ograft graftometer of skin graftoxia scleroderma will be sclerograft sclerograftograft sclerosis patients with systemic sclerosis.

Source link: https://clinicaltrials.gov/ct2/show/NCT05482594


High Definition Single Cell Analysis in Colorectal Cancer

Using single-cell high-content analysis, including gene copy number variation and the ability to identify one or more biopsies from patients with surgically resected colorectal cancer metastases to the liver, we were able to determine the consistency between solid tumor touch preparations and liquid biopsies from solid tumor touch preparations and liver biopsies from patients with surgically resected colorectal tumor metastases to the liver and the patient population. Comparing the two pre-resection liquid biopsy samples obtained one week before and on the day of surgery to show the technical reliability and reproducibility of the bio-signatures. Compare biosignatures between resected metastatic liver tumor tissue, primary colon tumor tissue, and pre-surgical blood samples. Compare biosignatures between blood samples before and resection with those obtained after resection and at the time of recurrence. Patients obtain blood 1 week before and after surgery on the same day, 1 week and 3 months after surgery.

Source link: https://clinicaltrials.gov/ct2/show/NCT02809716

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions